Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lane Labs restitution

This article was originally published in The Tan Sheet

Executive Summary

Consumers who purchased Lane Labs-USA's BeneFin, MGN-3 or SkinAnswer between Sept. 22, 1999 and July 12, 2004 are eligible for a partial refund of purchase price and shipping and handling costs through a court-mandated restitution program, FDA announces Aug. 17. Consumer restitution was ordered by New Jersey District Court in July 2004 and upheld by a U.S. appellate court in October 2005 (1"The Tan Sheet" Oct. 31, 2005, In Brief). Lane Labs argued the Federal Food, Drug & Cosmetics Act did not give the U.S. District Court power to mandate consumer restitution. Upholding the ruling in favor of FDA, the U.S. Court of Appeals for the Third Circuit determined consumer restitution is not prohibited by the Act and furthers the purpose of the statute...

You may also be interested in...

Lane Labs

District Court has the power to order consumer restitution under the Federal Food, Drug & Cosmetic Act, the U.S. Court of Appeals for the Third Circuit rules Oct. 21. The decision upholds a July 2004 New Jersey District Court opinion ordering Allendale, N.J.-based Lane Labs to pay consumer redress for marketing dietary supplements, such as BeneFin, as cancer therapies (1"The Tan Sheet" July 19, 2004, p. 9). According to the appellate court, consumer restitution is in accordance with established case law and the legislative history of the FD&C Act as it is not prohibited by the Act and furthers the purpose of the statute. The Court concedes that the analytic framework used in reaching the decision has been challenged by several cases but deems the cases to be "merely bumps in the road and not...roadblocks to the conclusions we have reached." The case was argued June 30 (2"The Tan Sheet" July 4, 2005, p. 16)...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts